News AHA: AZ's baxdrostat impresses in resistant hypertension AstraZeneca's data reveal for resistant hypertension treatment baxdrostat suggests its optimism about big sales for the drug could be justified.
News AZ's Q3 sales reach record $15bn, but it holds guidance AstraZeneca takes another step forwards towards its target of growing revenues to $80bn by 2030, as quarterly sales top $15bn for the first time.
News AZ trumpets results for new injectable C5 drug for gMG AstraZeneca's gefurulimab could give gMG patients the first treatment option that they can self-administer at home once a week.
News AZ, Organon fall foul of UK's code on pharma promotion AstraZeneca and Organon have breached the UK pharma industry's code of practice with promotions for an asthma drug and a contraceptive implant.
News ESMO: Datroway, Trodelvy lay claim to frontline TNBC therapy Two TROP2-targeting drugs, Datroway and Trodelvy, have new data suggesting they could become first-line options for triple-negative breast cancer.
News Amgen, AZ's Tezspire challenges Dupixent in nasal polyps Amgen and AstraZeneca's fast-growing asthma drug Tezspire is now poised to take on rival Dupixent in chronic rhinosinusitis with nasal polyps.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.